JAZZ's Xywav Gets Orphan Drug Exclusivity for Hypersomnia

Published on January 4, 2022

The FDA bestows an Orphan Drug Exclusivity to Jazz's (JAZZ) Xywav for treating idiopathic hypersomnia in adults. This is the second Orphan Drug Exclusivity for the drug.

Continue reading on website
Other news

Israel’s cybersecurity startups post another record year in 2021

January 4, 2022
Yonit Wiseman Contributor Yonit Wiseman, associate at YL Ventures, champions the Israeli cybersecurity community through technological due diligence and provides value-add support to the firm’s portfolio companies. Over the past decade, the Israeli cybersecurity industry has secured its place as a formidable wellspring of technological innovation. No longer famous

The 5 Best Performing Pure Play Electric Vehicle Stocks of 2021

January 4, 2022
The electric vehicle (EV) industry is expected to dominate the automotive industry over the next couple of decades, with increasing support from governments and consumers' growing uptake. Furthermore, rising crude...